Nimbus raises $65M to build pipeline

Nimbus Therapeutics LLC (Cambridge, Mass.) raised $65 million in a financing led by existing investor Atlas Venture. Also participating were existing investors SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, Lightstone Ventures and Schrödinger.

Since its founding in 2009, the computational chemistry company has used a business model in which its programs are housed in separate subsidiaries for the express purpose of making them easier to sell off early in the development process. The company’s partners include Celgene Corp. (NASDAQ:CELG) and Gilead Sciences Inc. (NASDAQ:GILD) (see BioCentury Innovations, Oct. 5, 2017)...